Seeing Is Believing
Currently out of the existing stock ratings of Carl Byrnes, 40 are a BUY (81.63%), 9 are a HOLD (18.37%).
Analyst Carl Byrnes, currently employed at NORTHLAND CAPITAL MARKETS, carries an average stock price target met ratio of 26.28% that have a potential upside of 24.11% achieved within 115 days.
Carl Byrnes’s has documented 94 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BWAY, Brainsway Ltd at 03-Oct-2024.
Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 4/16/2020. The price target of $42 was fulfilled within 21 days with a profit of $6.14 (17.12%) receiving and performance score of 8.15.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$16
$13.97 (688.18%)
$16
1 months 3 days ago
(02-Oct-2024)
0/9 (0%)
$14.18 (779.12%)
Buy
$6
$3.97 (195.57%)
$8
2 months 23 days ago
(13-Aug-2024)
0/9 (0%)
$4.2 (233.33%)
Hold
$2.5
$0.47 (23.15%)
4 months 16 days ago
(20-Jun-2024)
2/4 (50%)
$0.21 (9.17%)
14
Hold
$9
11 months 16 days ago
(20-Nov-2023)
4/8 (50%)
$2.84 (46.10%)
92
Hold
$3
$0.97 (47.78%)
1 years 7 months 16 days ago
(20-Mar-2023)
4/7 (57.14%)
$1.46 (94.81%)
80
Which stock is Carl Byrnes is most bullish on?
Which stock is Carl Byrnes is most reserved on?
What Year was the first public recommendation made by Carl Byrnes?